Insight Molecular Diagnostics

Update in progress

IMDX (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryDiagnostics & Research

Insight Molecular Diagnostics Inc. is a precision diagnostics company serving the United States and internationally. It develops and commercializes laboratory-developed tests, kitted research-use-only tests, and kitted clinical tests. Its products include DetermaCNI and DetermaIO, plus GraftAssureCore, -IQ, and -Dx for transplant monitoring. The company also offers biomarker discovery, assay development, and trial support, and collaborates with Bio-Rad. Formerly OncoCyte, renamed in 2025; founded 2009 and based in Nashville.

Company score

Sentiment: 0.21; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.04; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.01; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.02; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.11; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive